Powered by Advanced and Clinically Tested Bioprinting Technologies
PrintBio is the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. Leveraging first in human clinical experience, PrintBio is developing an array of products, beginning with 3DMatrix™, a 3D-printed monofilament bioresorbable surgical mesh (pending 510(k) FDA approval), utilizing its proprietary technologies clinically tested in patients.
Science & Technology
Technologies Tested in Patients
PrintBio’s pioneering approach develops products and living tissue implants with structural and functional integrity, based on a four-part technology platform that was developed to support an FDA-allowed IND for Aureo™, an ear bioprinted using cells harvested and expanded from the patient, by 3D Bio Theraeputics, and implanted in 2 patients born with Congenital Microtia.
This platform includes:
- A novel and proprietary 3D-bioprinter (GMPrint™)
- A unique collagen-based bio-ink (ColVivo™)
- A specialized cell culture system
- An implantable monofilament resorbable protective shell
(Overshell Technology)
Our Products
PrintBio has developed unique capabilities, materials and technologies that enable the creation of living tissue implants for therapeutic applications.
Leveraging this material science, regulatory and clinical experience, PrintBio is preparing to launch its first product that provides physicians with unprecedented capabilities in managing their patients, 3DMatrix™, a 3D-printed monofilament bioresorbable surgical mesh, pending 510(k) FDA approval.
Investor Relations
Corporate Profile
PrintBio is a clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products, and living tissues and organs, engineered and produced on-demand for patients.
